Clinical Trials Browser

Phase 1 × Unknown × Hematologic Diseases × Clear all

Hematologic Diseases

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasm, Residual, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04243434 2020-04-16

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Phase 1 Unknown

56 enrolled

Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms

Clinical Trials

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients